Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
21.78
-0.11 (-0.50%)
At close: Jun 27, 2025, 4:00 PM
22.00
+0.22 (1.01%)
Pre-market: Jun 30, 2025, 7:37 AM EDT
Catalyst Pharmaceuticals Revenue
Catalyst Pharmaceuticals had revenue of $141.42M in the quarter ending March 31, 2025, with 43.56% growth. This brings the company's revenue in the last twelve months to $534.65M, up 29.97% year-over-year. In the year 2024, Catalyst Pharmaceuticals had annual revenue of $491.73M with 23.49% growth.
Revenue (ttm)
$534.65M
Revenue Growth
+29.97%
P/S Ratio
4.87
Revenue / Employee
$2,953,845
Employees
181
Market Cap
2.66B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 491.73M | 93.53M | 23.49% |
Dec 31, 2023 | 398.20M | 184.00M | 85.90% |
Dec 31, 2022 | 214.20M | 73.37M | 52.10% |
Dec 31, 2021 | 140.83M | 21.76M | 18.27% |
Dec 31, 2020 | 119.07M | 16.77M | 16.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CPRX News
- 3 days ago - Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga
- 19 days ago - Strong Inflows Make Catalyst Stock an Outlier - FXEmpire
- 19 days ago - 20 stocks you should avoid — no matter how well the market does - Market Watch
- 4 weeks ago - Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer - GlobeNewsWire
- 4 weeks ago - Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma - Seeking Alpha
- 7 weeks ago - Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 - GlobeNewsWire